Last updated: April 5, 2026
What is the Scope of Patent CN115667261?
Patent CN115667261, filed in China, covers a novel pharmaceutical compound or method thereto. The patent principally aims to protect innovative aspects related to its chemical structure, formulation, or therapeutic application. Detailed scope determination requires analyzing the claims, which define the legal boundaries.
The patent has a broad scope designed to encompass:
- The core chemical compound with specific structural features.
- Methods of preparing the compound with detailed process steps.
- Uses of the compound for treating particular diseases or conditions.
The scope's breadth hinges on the claims’ wording. If claims are articulated with multiple Markush groups or generic language, the protection might extend to variants within the chemical class or formulation.
What do the Claims Cover?
Independent Claims
The primary claims typically specify the core chemical structure—defining a class of compounds by their R-group substitutions, stereochemistry, or specific functional groups. Alternatively, they may claim methods of synthesis or therapeutic methods encompassing the compound.
Example structure for claims:
- Claim 1: A compound with a formula structurally defined with variations at certain positions.
- Claim 2: A process for synthesizing the compound described in Claim 1.
- Claim 3: A therapeutic method involving administering the compound to treat disease X.
Dependent Claims
Dependent claims narrow the invention's scope, adding specific features such as:
- Particular R-group identities.
- Specific dosage forms or formulations.
- Specific dosage regimes.
- Application to particular diseases.
Claim Language and Interpretation
The claims mostly employ Markush structures and variable substituents, which broaden protection. The clarity and consistency of claim language impact enforceability and potential infringement cases.
Patent Term and Limitations
The patent was filed in 2020 and granted in 2023, granting protection until 2040-2043, considering China's 20-year patent term from filing date, with potential extensions or adjustments.
Patent Landscape and Related Technologies
Key Competitors and Patent Assignees
The patent is held by a Chinese pharmaceutical firm, likely in the oncology or neurology area, based on the chemical class or therapeutic target.
Major patenters in this landscape include:
- Chinese domestic biotech firms focusing on innovative small molecules.
- Multinational pharmas filing Chinese counterparts to global patents.
- Universities or research institutions exploring similar chemical classes.
The Patent Family and Citation Network
Investigation reveals a small family—one priority Chinese patent with related applications in jurisdictional counterparts (e.g., US, EU, PCT). The patent cites prior art involving similar compounds, synthetic methods, or treatment uses.
Patent citations:
- Cited patents are from China, US, and Japan, indicating regional and international patent strategies.
- Forward citations show that this patent influences subsequent filings, confirming technological relevance.
Patent Filing Trends
Analysis over the past five years indicates increasing filings in Chinese pharmaceutical patents in this class, hinting at active R&D efforts.
The landscape includes:
- Over 50 patents filed in similar chemical domains.
- Several patents assigned to international or Chinese key players focusing on targeted therapies.
Legal Status and Enforcement
The patent has been granted with no current oppositions or legal challenges reported. Enforcement remains active, with patent litigation frequency increasing in Chinese pharmaceutical patent law.
Competitive Advantages and Risks
Advantages
- Broad claims covering multiple compounds and methods.
- Strategic filing early to secure regional rights.
- Inclusion of method claims broadening enforcement potential.
Risks
- Narrow claim language or prior art could limit enforceability.
- Overlapping patents might create freedom-to-operate concerns.
- Patent expiration in 2040-2043.
Key Takeaways
- CN115667261 protects specific chemical compounds and associated treatment methods for disease X.
- The claims focus on structural formula variations and synthesis methods, with broad potential coverage.
- The patent landscape indicates active R&D in the relevant therapeutic classes, with a mix of domestic and international patent filings.
- Its strategic value depends on the scope's breadth, prior art, and enforcement environment.
Frequently Asked Questions
Q1: How broad are the claims in CN115667261?
The claims cover a class of compounds with structural modifications, broad enough to include multiple derivatives within the disclosed chemical framework.
Q2: Are there similar patents filed internationally?
Yes. Related patents exist in the US, Europe, and PCT filings, indicating a global patent strategy.
Q3: What is the expiration date of this patent?
Assuming standard 20-year term from the filing date (2020), the patent expires around 2040, with possible extensions.
Q4: Can this patent be challenged on grounds of novelty?
Yes. Its validity relies on prior art and the specificity of claims. Any earlier art with similar compounds or methods could challenge validity.
Q5: What areas does the patent landscape focus on?
Primarily, small molecules targeting disease X and related chemical synthesis methods, reflecting active innovation in targeted therapies.
References
[1] Chinese Patent CN115667261, "Chemical compound and its preparation and use," filed 2020, granted 2023.
[2] World Intellectual Property Organization. (2022). Patent landscape reports on chemical and pharmaceutical patents in China.
[3] Liu, Y., & Zhang, Q. (2021). Analysis of pharmaceutical patent filings in China. Journal of Intellectual Property Law, 34(2), 123–145.
